gsk efimosfermin - Search News

News

GSK, liver disease

Reuters on MSN · 3d

GSK to buy liver disease drug for up to $2 billion

GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm Boston Pharmaceuticals, the British drugmaker said on Wednesday. Efimosfermin, a monthly subcutaneous injection,

The Pharma Letter · 2d

GSK to acquire rights to liver disease drug efimosfermin

Aiming to expand its hepatology portfolio, UK pharma major GSK (LSE: GSK) yesterday announced that it has entered into an agreement to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa.

Medical Dialogues · 2d

GSK to acquire liver disease drug Efimosfermin for up to USD 2 billion

London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies for patients with serious liver diseases, have announced that they

3don MSN

GSK to buy efimosfermin for up to $2 billion

British pharmaceutical giant GSK on Wednesday said it will buy efimosfermin, a phase III-ready potential specialty medicine ...

GSK to acquire Boston’s liver disease candidate efimosfermin in deal worth up to $2bn

GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in ...

GSK to buy experimental MASH drug for $1.2B upfront

GSK plans to purchase an experimental drug for the liver disease MASH from Boston Pharmaceuticals for $1.2 billion upfront.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results